Target-directed cancer: protein-ligand interactions
Drug Target Review
NOVEMBER 1, 2023
We have several exciting projects in various stages of discovery, but a small-molecule drug that is causing a lot of excitement at the moment is Capivasertib. Capivasertib originated from a collaboration between my former company Astex Pharmaceuticals and the ICR and was further developed by AstraZeneca.
Let's personalize your content